Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa

N Engl J Med. 2022 Jun 9;386(23):2243-2245. doi: 10.1056/NEJMc2202061. Epub 2022 May 4.

Authors

Glenda Gray¹, Shirley Collie², Ameena Goga¹, Nigel Garrett³, Jared Champion², Ishen Seocharan¹, Lesley Bamford⁴, Harry Moultrie⁵, Linda-Gail Bekker⁶

Affiliations

¹ South African Medical Research Council, Cape Town, South Africa.
² Discovery Health, Sandton, South Africa.
³ Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
⁴ National Department of Health, Pretoria, South Africa.
⁵ National Institute for Communicable Diseases, Johannesburg, South Africa.
⁶ University of Cape Town, Cape Town, South Africa linda-gail.bekker@hiv-research.org.za.

No abstract available

Publication types

Letter

MeSH terms

Ad26COVS1* / therapeutic use
BNT162 Vaccine* / therapeutic use
COVID-19* / prevention & control
Humans
SARS-CoV-2
South Africa
Vaccine Efficacy
Vaccines / therapeutic use

Substances

Ad26COVS1
Vaccines
BNT162 Vaccine

Supplementary concepts

SARS-CoV-2 variants

Grants and funding

INV-030342/GATES/Bill & Melinda Gates Foundation/United States